Heart hope for dialysis patients: common drug gets new test
NCT ID NCT05179668
Summary
This study tested whether a diabetes drug called dapagliflozin could improve heart health in people with kidney failure who need regular dialysis. Researchers gave 220 patients either the drug or a placebo pill daily for six months to see if it reduced heart muscle thickening, a common and serious problem in this group. The goal was to see if this medication, already used for other conditions, could help control heart disease risks in vulnerable dialysis patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dialyseinstitut Dr. Waller
Feldbach, 8330, Austria
-
Dialyseinstitut Gießauf GmbH
Graz, Austria
-
Hanusch Krankenhaus
Vienna, 1140, Austria
-
Klinik Donaustadt
Vienna, 1220, Austria
-
Klinik Favoriten
Vienna, 1100, Austria
-
Klinik Landstraße
Vienna, 1030, Austria
-
Krankenhaus Hietzing
Vienna, 1130, Austria
-
Medical University of Vienna
Vienna, 1090, Austria
-
Wiener Dialysezentrum
Vienna, 1220, Austria
Conditions
Explore the condition pages connected to this study.